Peripheral vascular effects of bufuralol in hypertensive and normal subjects: A comparison with propranolol and pindolol
- 32 Downloads
In a double-blind, single oral dose, crossover study, the effects of bufuralol (60 mg) on heart rate, blood pressure, and peripheral vascular responses were compared with those of propranolol (160 mg), pindolol (10 mg), and placebo in a group of 12 healthy volunteers.
All three beta-adrenoceptor antagonists reduced exercise tachycardia, but at the doses chosen the effects of bufuralol were less than those of propranolol.
Forearm blood flow was reduced by propranolol and pindolol, but not by bufuralol.
The antihypertensive and peripheral vascular effects of bufuralol (30–60 mg bd) were also compared with those of propranolol (40–80 mg bd) in a double-blind crossover study in 10 patients with mild hypertension.
Propranolol and bufuralol produced comparable reductions in systemic blood pressure over a two-week period, but the decreases in forearm and finger blood flow were greater with propranolol.
These studies suggest that bufuralol is a beta-adrenoceptor antagonist with antihypertensive properties, and that it produces less peripheral vasoconstriction than propranolol or pindolol.
Key wordsbufuralol propranolol pindolol peripheral blood flow systemic blood pressure beta-adrenoceptor antagonist hypertension adverse effects
Unable to display preview. Download preview PDF.
- Blaber LC (1982) A beta-adrenoceptor antagonist with bronchodilating properties. Br J Pharmacol 77: 400PGoogle Scholar
- Blaber LC, Burden DT, Eigenmann R, Gerold M (1984) The effects of bufuralol, a beta-adrenoceptor antagonist with predominant beta2-adrenoceptor agonist activity, in the cat and the dog. J Cardiovasc Pharmacol 6: 165–175Google Scholar
- Eckert M, Cocco G, Strozzi C, Heizmann P, Sfrisi C (1983) Relationship between pharmacokinetic and pharmacokinetic behaviour of bufuralol and its metabolite Ro 3-7410 in hypertensive patients. Eur J Clin Pharmacol 24: 479–484Google Scholar
- Hamilton TC, Parkes MW (1977) Bufuralol, a new beta-adrenoceptor blocking agent in a series of benzofuran-2-ethanolamines. Arzneimittelforsch/Drug Res 27 [II]: 1410–1417Google Scholar
- Hamilton TC, Chapman V (1978) Intrinsic sympathomimetic activity of beta-adrenoceptor blocking drugs at cardiac and vascular beta-adrenoceptors. Life Sci 23: 813–820Google Scholar
- Kilborn JR, Turner P (1974) Ro 3-4787, a new adrneoceptor blocking agent: Studies in normal volunteers. Br J Clin Pharmacol 1: 143–149Google Scholar
- Louis WJ, McNeill JJ, Jarrott B, Drummer OH (1983) Beta-adrenoceptor blocking drugs: Current status and the significance of partial agonist activity. Am J Cardiol 52: 104A-107AGoogle Scholar
- Magometschigg D, Bonelli G, Hitzenberger G, Kaik G, Korn A (1978) Decrease of peripheral resistance after acute intravenous application of a new beta-receptor blocking agent, bufuralol HCl. Int J Clin Pharmacol 16: 54–58Google Scholar
- McDevitt DG (1983) Beta-adrenoceptor blocking drugs and partial agonist activity: is it clinically relevant? Drugs 25: 331–338Google Scholar
- Svensson A, Gudbrandsson T, Sivertsson R, Hansson L (1982) Haemodynamic effects of metoprolol and pindolol: A comparison in hypertensive patients. Br J Clin Pharmacol 13: 259S-267SGoogle Scholar
- Whitney RJ (1952) The measurement of changes in human limbs. J Physiol (London) 121: 1–17Google Scholar
- Wright BM, Dore CF (1970) A random-zero sphygmomanometer. Lancet 1: 337–338Google Scholar